Zogenix, Inc.
5959 Horton St 5th floor
Emeryville
California
94608
United States
Website: http://www.zogenix.com/
Email: info@zogenix.com
335 articles about Zogenix, Inc.
-
Zogenix Provides Corporate Update and Reports Third Quarter 2020 Financial Results
11/9/2020
FINTEPLA® (fenfluramine) oral solution launched in the U.S. in late July for Dravet syndrome with high enrollment of physicians and patients into the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS) program
-
Zogenix Announces Date Change for Third Quarter 2020 Financial Results and Conference Call and Webcast to November 9
10/29/2020
Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it has changed the date of its previously announced earnings release and earnings call.
-
Zogenix to Release Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 10
10/26/2020
Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and nine months ended September 30, 2020 and host a corporate update conference call and webcast after the market close on Tuesday, November 10, 2020, at 4:30 PM Eastern Time. Conference Call Details Tuesday, November 10 , at 4:30 PM Eastern Tim
-
Zogenix Receives Positive CHMP Opinion for FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Patients with Dravet Syndrome
10/16/2020
Dravet syndrome is a rare , life-long, infant- and childhood- onset epilepsy associated with severe, treatment-resistant seizures CHMP positive opinion based on Phase 3 study data that demonstrat e d FINTEPLA ® significantly reduced convulsive seizure frequency in patients whose seizures were not adequately controlled on other medications, including stiripentol Final d ecision on Marketing Authorization Application expected by year-end 2020
-
Zogenix Presents New Data for FINTEPLA® in Dravet Syndrome at CNS 2020
10/15/2020
Interim data from open-label extension trial showedsubstantial seizure reductions were maintainedin patients treated with FINTEPLA® for up to two years
-
Zogenix Presents New Data at the World Muscle Society Conference 2020
10/2/2020
Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, and its subsidiary Modis Therapeutics, shared new data and information about MT1621, the company’s investigational therapy for Thymidine kinase 2 deficiency (TK2d), at this week’s International Congress of the World Muscle Society (WMS 2020). TK2d is an inherited mitochondrial DNA depletion syndrome that primarily affects
-
Zogenix, Inc. Prices $200.0 Million Convertible Senior Notes Offering
9/24/2020
Zogenix, Inc. announced the pricing of its offering of $200,000,000 aggregate principal amount of 2.75% convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
Zogenix, Inc. Announces Proposed Convertible Senior Notes Offering
9/22/2020
Zogenix, Inc. (Nasdaq: ZGNX) today announced its intention to offer, subject to market and other conditions, $200,000,000 aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Zogenix also expects to grant the initial purchasers of the notes an option to purchase, for set
-
CORRECTING and REPLACING - Zogenix Appoints Three Industry Leaders to Its Board of Directors
9/22/2020
Zogenix, a global biopharmaceutical company developing and commercializing rare disease therapies, announced the appointments of Caroline M. Loewy, Mary E. Stutts and Denelle J. Waynick to newly created seats on its Board of Directors, effective immediately.
-
Zogenix Announces Positive Top-Line Results from its Third Pivotal Phase 3 Clinical Trial (Study 3) of FINTEPLA® in Dravet Syndrome
9/10/2020
Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today reported positive top-line results from its third Phase 3 study (Study 3) of FINTEPLA® (fenfluramine) oral solution for the treatment of seizures associated with Dravet syndrome.
-
Zogenix Provides Corporate Update and Reports Second Quarter 2020 Financial Results
8/5/2020
Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced financial results for the three and six months ended June 30, 2020, and provided a corporate update
-
Zogenix to Release Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 5
7/29/2020
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and six months ended June 30, 2020, after the market close, and will host a corporate update conference call and webcast on Wednesday, August 5, 2020, at 4:30 PM Eastern Time. Conference Call Details Wednesday, August 5, at 4:30 PM Eastern Time / 1:30 PM Pacifi
-
FDA Approves FINTEPLA® (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome
6/26/2020
- FINTEPLA® significantly and substantially reduced convulsive seizure frequency in patients whose seizures were not adequately controlled on other medications, as observed in two phase 3 placebo-controlled clinical trials - Commercial launch planned for July 2020 - Zogenix to host an investor call tomorrow, June 26, at 8:30 AM ET / 5:30 AM PT [25-June-2020]
-
Shares of Zogenix were up more than 16% in premarket trading following the regulatory approval of the epilepsy drug Fintepla for the treatment of seizures associated with Dravet syndrome, a rare form of epilepsy, in patients ages two and above.
-
FDA Approves FINTEPLA® (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome
6/26/2020
FINTEPLA ® significantly and substantially reduced convulsive seizure frequency in patients whose seizures were not adequately controlled on other medications, as observed in two phase 3 placebo-controlled clinical trials Commercial launch planned for July 2020 Zogenix to host an investor call tomorrow, June 26, at 8:30 AM ET / 5:30 AM PT EMERYVILLE, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therap
-
Wrapping up June and ahead of the July 4 holiday, the U.S. Food and Drug Administration (FDA) has a busy two-week period coming up for drug approvals. Here’s a look.
-
Zogenix Introduces New Resources for Dravet Syndrome SiblingsNew materials were created in collaboration with the Dravet Syndrome Foundation to support and celebrate the brothers and sisters of those living with a rare and severe epilepsy
6/12/2020
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced the introduction in the U.S. of a new suite of materials to better support and celebrate siblings of those living with Dravet syndrome. Dravet syndrome is a rare, severe childhood-onset epilepsy marked by frequent debilitating seizures, lifelong developmental and motor impairments, and an increased risk of sudden death. The sev
-
Zogenix Launches Shine Forward with Dravet, a New Source of Inspiring Ideas for Parents of Children Living with Dravet Syndrome
5/15/2020
Unique tips and tools informed by the Dravet syndrome community are designed to help parents and siblings of a child with Dravet stay positive and connected.
-
Zogenix to Participate in the BofA Securities 2020 Virtual Healthcare Conference
5/6/2020
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will participate in a fireside chat on Wednesday, May 13, 2020, at the BofA Securities 2020 Virtual Healthcare Conference.
-
Zogenix Provides Corporate Update and Reports First Quarter 2020 Financial Results
5/5/2020
Zogenix, Inc., a global pharmaceutical company developing rare disease therapies, announced financial results for the three months ended March 31, 2020, and provided a corporate update.